Compare Digital Realty Trust, Inc. (DLR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Sanofi SA — how do they compare? Digital Realty Trust, Inc. trades at $176.26 (market cap $66.95B), while Sanofi SA trades at $40.36 (market cap $96.81B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and Sanofi SA for 94 Days on average.
| DLR | SNY | |
|---|---|---|
Market Cap | $66.95B | $96.81B |
Volume | 1,766,660 | 2,081,815 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $52.34 |
52-Week Low | $147.93 | $39.51 |
Typical Hold Time | 94 Days | 94 Days |
Enterprise Value | $85.67B | $116.20B |
Dividend Yield | 2.7% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLR trades at $176.07, down 4.65% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamental momentum, with Q2 2026 EPS beating expectations at $1.21 versus $0.4829, and revenue growth from $6.11B in 2025 to a projected $6.8B in 2026. Recent news highlights expansion in AI infrastructure, including a collaboration with Blackfuel and a new Los Angeles cable landing station, positioning the company to capitalize on data center demand.
The outlook for DLR is positive, driven by robust AI-driven demand and a record backlog, though high valuation multiples like a P/E of 88.03 pose a risk if growth slows. Analyst consensus is strongly bullish with a $222.35 price target, but investors face risks from significant capital expenditures and debt levels.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
